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Abstract 15 
The d
6 
metal complexes of thiourea derivatives were synthesized to investigate its 16 
cytotoxicity. Treatment of various N-phenyl-N´ pyridyl/pyrimidyl thiourea ligands with half-17 
sandwich d
6 
metal precursors yielded a series of cationic complexes. Reactions of ligand (L1-L3) 18 
with [(p-cymene)RuCl2]2 and [Cp*MCl2]2 (M = Rh/Ir) led to the formation of a series of cationic 19 
complexes bearing general formula [(arene)M(L1)к2(N,S)Cl]
+
, [(arene)M(L2)к2(N,S)Cl]
+
 and 20 
[(arene)M(L3)к2(N,S)Cl]
+
 [arene = p-cymene, M = Ru (1, 4, 7); Cp*, M = Rh (2, 5, 8); Cp*, Ir (3, 21 
6, 9)]. These compounds were isolated as their chloride salts. X-ray crystallographic studies of 22 
the complexes revealed the coordination of the ligands to the metal in a bidentate chelating N,S- 23 
manner. Further the cytotoxicity studies of the thiourea derivatives and its complexes evaluated 24 
against HCT-116 (human colorectal cancer), MIA-PaCa-2 (human pancreatic cancer) and 25 
ARPE-19 (non-cancer retinal epithelium) cancer cell lines showed that the thiourea ligands 26 
displayed no activity. Upon complexation however, the metal compounds possesses cytotoxicity 27 
and whilst potency is less than cisplatin, several complexes exhibited greater selectivity for 28 
HCT-116 or MIA-PaCa-2 cells compared to ARPE-19 cells than cisplatin in vitro. Rhodium 29 
complexes of thiourea derivatives were found to be more potent as compared to ruthenium and 30 
iridium complexes. 31 
Keywords: Ruthenium, rhodium, iridium, thiourea, chemosensitivity.  32 
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Introduction 33 
Half-sandwich arene d
6 
metal complexes (arene = p-cymene and its derivatives) have 34 
been given much importance owing to their clinical and industrial applications.
[1]
 These 35 
organometallic compounds have been widely exploited for their medicinal applications and it has 36 
been proved that these complexes bear the potential to act as metal based anti-cancer drugs.
[2,3]
 In 37 
particular, two half-sandwich ruthenium complexes namely [Ru(η6-arene)Cl(en)]+ (en = 38 
ethylenediamine) developed by Chen et.al and [Ru(p-cymene)Cl2(PTA)], developed by 39 
Allardyce et.al termed RAPTA-C (PTA = 1,3,5-triaza-7-phosphaadamantane) have been found 40 
to exhibit excellent cytotoxic activity in vitro and anticancer activity in vivo.
[4,5]
 The cyclic arene 41 
ligands in these complexes are relatively inert towards substitution, it protects the metal‟s 42 
oxidation state and it also influences hydrophobicity and interaction with biomolecules.
[6,7]
 It has 43 
been observed that the mode of action of these compounds depends strongly on the nature of the 44 
chelating ligand.
[8]
 In this regard it is important to choose a particular chelating ligand system 45 
with known bioactive properties.
[9]
 Nevertheless pentamethylcyclopentadienyl rhodium and 46 
iridium complexes have also been explored and studied for their antitumor activities due to the 47 
inert facial co-ligand Cp* which offers several advantages.
[10]
 48 
Much interest has been paid towards the synthesis and development of transition metal 49 
complexes containing thiourea ligands because of their interesting binding modes.
[11]
 These 50 
ligands can coordinate metal ion in a variety of coordination modes because of the presence of 51 
various donor atoms such as N´, O, N´ and S.
[12]
 Thiourea ligands can coordinate transition metal 52 
in either neutral bidentate (O, N), monobasic bidentate (O, S), and neutral monodentate (S) 53 
modes.
[12-14]
 Numerous thiourea derivatives and its metal complexes are known to exhibit a wide 54 
range of biological activities such as antifungal, antibacterial, antimalarial and antitumor, 55 
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activities.
[15-18]
 Introduction of various substituents into the thiourea ligand can definitely 56 
increase the selectivity towards the metal ion and is also expected to alter the coordination modes 57 
of these ligands. Since the choice of ligands plays a crucial role in determining the biological 58 
properties of the complexes we decided to substitute aryl group with pyridyl group and 59 
determine the coordination properties of pyridyl thiourea derivatives. Previous studies in this 60 
laboratory have reported some half-sandwich arene ruthenium, rhodium and iridium complexes 61 
with pyridyl thiourea ligands
[19,20]
 and in this study, we report the synthesis, structural and 62 
cytotoxic activity against cancer and non-cancer cell lines in vitro of p-cymene ruthenium, Cp* 63 
rhodium and Cp* iridium complexes containing thiourea derivatives. Ligands used in the present 64 
study are shown in Chart 1. 65 
Experimental 66 
Materials and Methods 67 
The reagents were of commercial quality and used without further purification. Metal 68 
salts RuCl3.nH2O, RhCl3.nH2O and IrCl3.nH2O were purchased from Arora Matthey Limited. α-69 
phellandrene, pentamethylcyclopentadiene, 2-aminopyridine, 2-aminopyrimidine and 2-amino-4-70 
methyl-pyridine were purchased from Sigma Aldrich. Phenyl isothiocyanate was obtained from 71 
Spectrochem. The solvents were dried and distilled prior to use according to standard 72 
procedures.
[21]
 Precursor metal complexes [(p-cymene)RuCl2]2 and [Cp*MCl2]2 (M = Rh/Ir) 73 
were prepared according to the published procedures.
[22,23]
 The thiourea ligands 1-phenyl-3-74 
(pyridine-2-yl)thiourea (L1), 1-phenyl-3-(pyrimidin-2-yl)thiourea (L2) and 1-(4-methylpyridin-75 
2-yl)-3-phenylthiourea (L3) were prepared according to reported procedures.
[24]
 
1
H NMR spectra 76 
were recorded on a Bruker Avance II 400 MHz spectrometer using CDCl3 as solvent; chemical 77 
shifts were referenced to TMS. Infrared spectra (KBr pellets; 400-4000 cm
-1
) were recorded on a 78 
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Perkin-Elmer 983 spectrophotometer. Mass spectra were recorded with Q-Tof APCI-MS 79 
instrument (model HAB 273) using acetonitrile as solvent. Elemental analyses of the complexes 80 
were carried out on a Perkin-Elmer 2400 CHN/S analyzer. 81 
Structure determination by X-ray crystallography 82 
Suitable single crystals of complexes were obtained by slow diffusion of hexane into 83 
dichloromethane solution. Single crystal data for the complexes were collected with an Oxford 84 
Diffraction Xcalibur Eos Gemini diffractometer using graphite monochromated Mo-Kα radiation 85 
(λ = 0.71073 Å). The strategy for the data collection was evaluated using the CrysAlisPro CCD 86 
software. Crystal data were collected by standard „„phi–omega scan‟‟ techniques and were scaled 87 
and reduced using CrysAlisPro RED software. The structures were solved by direct methods 88 
using SHELXS-97 and refined by full-matrix least squares with SHELXL-97 refining on F
2
. 
[25, 
89 
26]
 The positions of all the atoms were obtained by direct methods. Metal atoms in the complex 90 
were located from the E-maps and all non-hydrogen atoms were refined anisotropically by full-91 
matrix least-squares. Hydrogen atoms were placed in geometrically idealised positions and 92 
constrained to ride on their parent atoms with C-H distances in the range 0.95-1.00 Angstrom. 93 
Isotropic thermal parameters Ueq were fixed such that they were 1.2Ueq of their parent atom Ueq 94 
for CH's and 1.5Ueq of their parent atom Ueq in case of methyl groups. Crystallographic and 95 
structure refinement parameters for the complexes are summarized in Table 1 and selected bond 96 
lengths and bond angles are presented in Table 2. Figures 2-4 were drawn with ORTEP3 97 
program whereas Figures 5 and 6 was drawn using MERCURY 3.6 program.
[27]
 98 
Because of poor crystal quality the crystal structure of complex (1) has low theta value, 99 
we have presented the data here only to establish the structure. Crystal structure of complex (5) 100 
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contains solvent molecule (CHCl3) in the solved structure. The crystal structure of complex (6) 101 
contains DCM and pentane molecules, which has been removed by SQUEEZE method.
[28]
 102 
Cell lines testing, culture conditions and cytotoxicity against cell lines 103 
The cytotoxic activity of the thiourea derivatives and its corresponding ruthenium, 104 
rhodium and iridium complexes were evaluated against HCT-116 colorectal carcinoma and 105 
MIA-PaCa-2 pancreatic carcinoma cell lines and the non-cancer ARPE-19 (human epithelial cell 106 
line derived from the retina) cell line. These cell lines were purchased from the American Type 107 
Culture Collection (ATCC) and the reagents used were purchased from Sigma Aldrich Co. Ltd 108 
(Dorset, UK) unless otherwise stated. Cytotoxicity of thiourea ligands and compounds were 109 
evaluated using the standard MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 110 
bromide) cellular viability assay as follows. Cells were inoculated into 96 well plates at 1.5 x 10
3 
111 
cells per well and incubated for 24 hours at 37 
°
C in an atmosphere of 5% CO2 prior to drug 112 
exposure. The thiourea ligands and complexes (1-9) were all dissolved in DMSO at a 113 
concentration of 100 mM and diluted further with medium to obtain drug solutions ranging from 114 
0.5 to 100 μM. The final DMSO concentration was 0.1% (v/v), which is nontoxic to cells. 115 
Cisplatin was dissolved in phosphate buffered saline at a stock concentration of 25 mM. Cells 116 
were exposed to drug for 96 hours and cell survival was determined using the MTT assay.
[29,30]
 117 
Briefly, 20 µL of MTT (0.5 mg/ml) in phosphate buffered saline was added to each well and it 118 
was further incubated at 37 
°
C for 4 hours in an atmosphere containing 5% CO2. The solution 119 
was then removed and the formazan crystals formed were dissolved in 150 µM DMSO. The 120 
absorbance of the solution was recorded at 550 nm using an ELISA spectrophotometer. 121 
Percentage cell survival was calculated by dividing the true absorbance of treated cell by the true 122 
absorbance for controls (exposed to 0.1% DMSO). The IC50 values were determined from plots 123 
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of % survival against drug concentration. Each experiment was repeated three times and a mean 124 
value obtained and stated as IC50 (µM) ± SD. To compare the response of non-cancer cells to 125 
cancer cells, the selectivity index (SI) was calculated as the IC50 for ARPE-19 cells divided by 126 
the IC50 for either HCT-116 or MIA-PaCa-2 cells. Values >1 indicate that complexes have 127 
selective activity against cancer compared to non-cancer cells in vitro. 128 
General procedure for synthesis of metal complexes (1-9) 129 
A mixture of metal precursor [(p-cymeme)RuCl2]2 or [Cp*MCl2]2 (M = Rh/Ir) (0.1 130 
mmol) and thiourea derivatives (L1-L3) (0.2 mmol) were dissolved in dry acetone (10 mL) and 131 
stirred at room temperature for 8 hours (Scheme 1). A yellow colored compound precipitated out 132 
from the reaction mixture. The precipitate was filtered, washed with cold acetone (2 x 5 ml) and 133 
diethyl ether (3 x 10 ml) and air dried. 134 
[(p-cymene)Ru(L1)к2(N,S)Cl]Cl (1) 135 
Yield: 80 mg (74%); Anal. Calc for C22H25N3Cl2SRu (535.49); C, 49.34; H, 4.71; N, 7.85. 136 
Found: C, 49.43; H, 4.84; N, 7.96 %; FT-IR (KBr, cm
-1
): 3337(m), 2203(m), 1620(m), 1545(m), 137 
1443(m), 1484(m), 1231(m), 1122(m); 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 13.23 (s, 1H, 138 
NH), 12.01 (s, 1H, NH), 8.84 (dd, J = 4 and 4 Hz, 1H), 7.75 (t, J = 4 Hz, 1H), 7.55-7.61 (m, 3H), 139 
7.39 (t, J = 8 Hz, 2H), 7.30 (t, J = 8 Hz, 1H), 7.15 (t, J = 4 Hz, 1H), 5.47 (d, J = 8 Hz, 1H), 5.39 140 
(d, J = 4 Hz, 1H, CH(p-cym)), 5.23 (t, J = 8 Hz, 2H, CH(p-cym)), 2.74 (sept, 1H, CH(p-cym)), 1.89 (s, 141 
3H, CH(p-cym)), 1.18 (dd, 6H, J = 4 and 4 Hz, CH(p-cym));
 13
C NMR (100 MHz, CDCl3): δ = 142 
176.94, 164.59, 153.65, 151.93, 139.26, 135.40, 128.12, 126.87, 124.26, 120.37, 116.24 (C-L1), 143 
106.01, 99.18, 85.71, 84.42, 84.11, 83.27, 29.69, 21.42, 21.24, 17.18 (C-p-cym); HRMS-APCI 144 
(m/z) [Found (Calcd)]: [464.0753 (464.0734)] [M-2H-2Cl+H]
+
. 145 
[Cp*Rh(L1)к2(N,S)Cl]Cl (2) 146 
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Yield: 79 mg (73%); Anal. Calc for C22H26Cl2N3SRh (538.33); C, 49.08; H, 4.87; N, 7.81. 147 
Found: C, 49.17; H, 4.95; N, 7.93 %; FT-IR (KBr, cm
-1
): 3370(w), 3151(m), 1611(m), 1603(m), 148 
1568(m), 1536(m), 1228(m), 1135(m), 1122(m); 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 13.41 149 
(s, 1H, NH), 12.07 (s, 1H, NH), 8.74 (d, J = 8 Hz, 1H), 7.85 (t, J = 8 Hz, 1H), 7.73 (d, J = 8 Hz, 150 
2H), 7.60 (d, J = 8 Hz, 2H), 7.45 (t, J = 8 Hz, 2H), 7.37 (t, J = 8 Hz, 1H), 1.54 (s, 15H, CH(Cp*)); 151 
13
C NMR (100 MHz, CDCl3): δ = 176.66, 152.33, 151.74, 140.56, 136.38, 129.10, 127.93, 152 
125.70, 122.18, 117.17, (C-L2), 97.07 (Cp*ipso), 8.78 (Cp*Me); HRMS-APCI (m/z) [Found 153 
(Calcd)]: [466.0820 (466.0824)] [M-2H-2Cl+H]
+
. 154 
[Cp*Ir(L1)к2(N,S)Cl]Cl (3) 155 
Yield: 96 mg (76%); Anal. Calc for C22H26Cl2N3SIr (627.64); C, 42.10; H, 4.18; N, 6.69. Found: 156 
C, 42.25; H, 4.27; N, 6.79 %; FT-IR (KBr, cm
-1
): 3338(w), 3186(m), 1617(m), 1591(w), 157 
1544(m), 1484(m), 1233(m), 1159(m); 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 13.25 (s, 1H, 158 
NH), 12.03 (s, 1H, NH), 8.68 (d, J = 4 Hz, 1H), 7.70-7.80 (m, 2H), 7.58 (d, J = 8 Hz, 2H), 7.45 159 
(t, J = 8 Hz, 2H), 7.38 (d, J = 8 Hz, 2H), 7.19 (t, J = 8 Hz, 1H), 1.54 (s, 15H, CH(Cp*)); 
13
C NMR 160 
(100 MHz, CDCl3): δ = 176.32, 153.61, 151.94, 140.21, 135.91, 129.07, 126.42, 124.12, 122.12, 161 
117.17, (C-L1), 97.07 (Cp*ipso), 8.55 (Cp*Me); HRMS-APCI (m/z) [Found (Calcd)]: [556.1381 162 
(556.1398)] [M-2H-2Cl+H]
+
. 163 
[(p-cymene)Ru(L2)к2(N,S)Cl]Cl (4) 164 
Yield: 84 mg (78%); Anal. Calc for C21H24Cl2N4SRu (536.48); C, 47.01; H, 4.51; N, 10.44. 165 
Found: C, 47.10; H, 4.62; N, 10.56 %; FT-IR (KBr, cm
-1
): 3370(w), 3298(m), 3176(m), 166 
2965(m), 1618(m), 1583(m), 1561(m), 1474(m), 1202(m), 1161(m); 
1
H NMR (400 MHz, 167 
CDCl3): δ (ppm) = 13.11 (s, 1H, NH), 9.14 (dd, J = 4 and 4 Hz, 1H), 8.78 (d, J = 4 Hz, 1H), 7.66 168 
(d, J = 8 Hz, 2H), 7.47 (d, J = 8 Hz, 2H), 7.38 (t, J = 8 Hz, 1H), 7.27 (t, J = 4 Hz, 1H), 5.56 (d, J 169 
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= 4 Hz, 1H, CH(p-cym)), 5.50 (d, J = 4 Hz, 1H, CH(p-cym)), 5.38 (d, J = 4 Hz, 2H, CH(p-cym)), 281 170 
(sept, 1H, CH(p-cym)), 2.00 (s, 3H, CH(p-cym)), 1.25 (d, J = 4 Hz, 6H, CH(p-cym)); 
13
C NMR (100 171 
MHz, CDCl3): δ = 177.08, 163.39, 160.45, 157.56, 136.28, 129.14, 128.05, 125.42, 118.18, (C-172 
L2), 107.60, 100.45, 86.73, 85.60, 85.13, 84.74, 30.70, 22.41, 22.19, 18.20 (C-p-cym); HRMS-173 
APCI (m/z) [Found (Calcd)]: [465.0685 (465.0687)] [M-2H-2Cl+H]
+
. 174 
[Cp*Rh(L2)к2(N,S)Cl]Cl (5) 175 
Yield: 78 mg (73%); Anal. Calc for C21H25Cl2N4SRh (539.32); C, 46.77; H, 4.67; N, 10.39. 176 
Found: C, 46.87; H, 4.75; N, 10.48 %; FT-IR (KBr, cm
-1
): 3358(w), 3262(m), 3174(m), 177 
1618(m), 1575(m), 1475(m), 1441(m), 1206(m), 1159(m); 
1
H NMR (400 MHz, CDCl3): δ 178 
(ppm) = 9.09 (dd, J = 4 and 4 Hz, 1H), 8.93 (s, 1H, NH), 7.73 (d, J = 8 Hz, 2H), 7.56 (t, J = 8 179 
Hz, 2H), 7.50 (d, J = 8 Hz, 1H), 7.38-7.42 (m, 2H), 1.66 (s, 15H, CH(Cp*)); 
13
C NMR (100 MHz, 180 
CDCl3): δ = 176.23, 161.15, 161.03, 156.27, 136.15, 129.17, 128.14, 125.64, 118.75, (C-L2), 181 
89.91 (Cp*ipso), 8.51 (Cp*Me); HRMS-APCI (m/z) [Found (Calcd)]: [467.0784 (467.0777)] [M-182 
2H-2Cl+H]
+
. 183 
[Cp*Ir(L2)к2(N,S)Cl]Cl (6) 184 
Yield: 104 mg (83%); Anal. Calc for C21H25Cl2N4SIr (628.63); C, 40.12; H, 4.01; N, 8.91. 185 
Found: C, 40.23; H, 4.11; N, 9.03 %; FT-IR (KBr, cm
-1
): 3374(w), 3252(m), 3171(m), 1616(m), 186 
1585(m), 1463(m), 1204(m), 1162(m), 843(s); 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 9.03 (dd, 187 
J = 4 and 4 Hz, 1H), 8.87 (s, 1H, NH), 7.70 (d, J = 8 Hz, 2H), 7.55 (t, J = 8 Hz, 2H), 7.50 (d, J = 188 
8 Hz, 1H), 7.35-7.38 (m, 2H), 1.65 (s, 15H, CH(Cp*)); 
13
C NMR (100 MHz, CDCl3): δ = 175.67, 189 
161.55, 161.06, 156.71, 136.26, 129.12, 128.11, 125.75, 119.01, (C-L2), 97.40 (Cp*ipso), 8.84 190 
(Cp*Me); HRMS-APCI (m/z) [Found (Calcd)]: [557.1355 (557.1351)] [M-2H-2Cl+H]
+
. 191 
[(p-cymene)Ru(L3)к2(N,S))Cl]Cl (7) 192 
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Yield: 78 mg (71%); Anal. Calc for C23H27Cl2N3SRu (549.52); C, 50.27; H, 4.95; N, 7.65. 193 
Found: C, 50.38; H, 5.06; N, 7.73 %; FT-IR (KBr, cm
-1
): 3356(m), 3160(m), 1618(m), 1594(m), 194 
1547(m), 1487(m), 1224(m), 1125(m); 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 13.12 (s, 1H, 195 
NH), 12.12 (s, 1H, NH), 8.72 (d, J = 4 Hz, 1H), 7.64 (d, J = 8 Hz, 2H), 7.46 (t, J = 8 Hz, 3H), 196 
7.37 (t, J = 8 Hz, 1H), 7.04 (d, J = 4 Hz, 1H), 2.45 (s, 3H, CH3(py)) 5.51 (d, J = 4 Hz, 1H, CH(p-197 
cym)), 5.43 (d, J = 4 Hz, 1H, CH(p-cym)), 5.27 (t, J = 8 Hz, 1H, CH(p-cym)), 2.80 (sept, 1H, CH(p-cym)), 198 
1.96 (s, 3H, CH(p-cym)), 1.24 (dd, J = 4 and 4 Hz, 6H, CH(p-cym)); 
13
C NMR (100 MHz, CDCl3): δ 199 
= 178.07, 153.75, 152.97, 152.34, 136.46, 129.07, 127.78, 125.23, 122.92, 117.42, 20.93 (C-L3), 200 
106.97, 100.02, 86.57, 85.30, 85.02, 84.15, 30.68, 22.42, 22.24, 18.21 (C-p-cym); HRMS-APCI 201 
(m/z) [Found (Calcd)]: [478.0902 (478.0891)] [M-2H-2Cl+H]
+
. 202 
[Cp*Rh(L3)к2(N,S)Cl]Cl (8) 203 
Yield: 86 mg (78%); Anal. Calc for C23H28Cl2N3SRh (552.36); C, 50.01; H, 5.11; N, 7.61. 204 
Found: C, 50.13; H, 5.27; N, 7.75 %; FT-IR (KBr, cm
-1
): 3371(s), 3120(m), 1619(m), 1602(w), 205 
1585(s), 1523(s), 1223(m), 1140(m); 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 13.20 (s, 1H, NH), 206 
12.10 (s, 1H, NH), 8.55 (d, J = 4 Hz, 1H), 7.60 (d, J = 8 Hz, 2H), 7.47 (t, J = 8 Hz, 2H), 7.43 (t, J 207 
= 4 Hz, 2H), 7.09 (d, J = 4 Hz, 1H), 2.45 (s, 3H, CH3(py)), 1.53 (s, 15H, CH(Cp*)); 
13
C NMR (100 208 
MHz, CDCl3): δ = 176.78, 153.30, 151.55, 151.20, 136.47, 129.08, 127.86, 125.70, 123.77, 209 
117.86, 21.03, (C-L3), 96.89 (Cp*ipso), 8.80 (Cp*Me); HRMS-APCI (m/z) [Found (Calcd)]: 210 
[480.0980 (480.0981)] [M-2H-2Cl+H]
+
. 211 
[Cp*Ir(L3)к2(N,S)Cl]Cl (9) 212 
Yield: 94 mg (73%); Anal. Calc for C23H28Cl2N3SIr (641.67); C, 43.05; H, 4.40; N, 6.55. Found: 213 
C, 43.16; H, 4.47; N, 6.64 %; FT-IR (KBr, cm
-1
): 3340(w), 2922(m), 1618(m), 1593(w), 214 
1541(m), 1489(m), 1232(m), 1189(m); 
1
H NMR (400 MHz, CDCl3): δ (ppm) = 13.07 (s, 1H, 215 
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NH), 12.04 (s, 1H, NH), 8.49 (d, J = 8 Hz, 1H), 7.55 (t, J = 8 Hz, 3H), 7.44 (t, J = 8 Hz, 2H), 216 
7.36 (t, J = 4 Hz, 1H), 7.01 (d, J = 4 Hz, 1H), 2.49 (s, 3H, CH3(py)), 1.52 (s, 15H, CH(Cp*)); 
13
C 217 
NMR (100 MHz, CDCl3): δ = 176.44, 153.54, 152.39, 150.85, 136.32, 129.12, 127.91, 125.64, 218 
123.77, 117.53, 20.94, (C-L3), 89.32 (Cp*ipso), 8.51 (Cp*Me); HRMS-APCI (m/z) [Found 219 
(Calcd)]: [570.1572 (570.1555)] [M-2H-2Cl+H]
+
. 220 
Results and discussion 221 
Synthesis of complexes 222 
The present work deals with the synthesis, characterization and chemosensitivity studies 223 
of arene d
6
 metal complexes containing thiourea derivatives. The metal complexes (1-9) were 224 
synthesized by the reaction of precursor complexes and thiourea derivatives (L1-L3) in acetone. 225 
Scheme 1 depicts the synthesis of the metal complexes containing thiourea derivatives. These 226 
complexes were isolated as ionic salts with chloride counter ion. The complexes were isolated as 227 
dark to light yellow solids in moderate yields and are non-hygroscopic. They are soluble in 228 
common organic solvents like acetonitrile, dichloromethane, chloroform, methanol and DMSO 229 
but insoluble in petroleum ether, hexane and diethyl ether. Single crystal X-ray diffraction 230 
analysis confirmed the coordination of the thiourea derivatives to the metal ion in bidentate 231 
chelating N,S- manner. Further the anti-cancer activity of the thiourea derivatives and its metal 232 
complexes were evaluated against two cancer cell lines and one non cancer cell line. 233 
Spectral studies of the complexes 234 
IR studies of metal complexes 235 
The preliminary confirmation of the formation of complexes was justified from their IR 236 
spectra. The appearance of the N-H stretching frequencies in the complexes around 3100-3370 237 
cm
-1
 indicates that the N-H group is not involved in coordination. The coordination of the thione 238 
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sulfur to the metal would result in the displacement of electrons towards the metal ion which will 239 
weaken the C=S bonds hence on complexation the C=S stretching vibrations is expected to 240 
decrease. Therefore on complexation the C=S stretching frequencies appeared in the lower 241 
frequency region around 1202-1233 cm
-1 
as compared to the free ligand suggesting the 242 
coordination of thione sulfur. The C=N stretching vibration decreases slightly and was observed 243 
in the range of 1598-1620 cm
-1
 which indicates involvement of pyridyl/pyrimidyl nitrogen in 244 
coordination. 245 
1
H NMR studies of metal complexes 246 
The 
1
H NMR spectra of the complexes are provided in the supplementary information 247 
(Figures S1-S9). The formation of the complexes was supported by the 
1
H NMR studies. The 248 
appearance of the ligand proton signals in addition to the p-cymene and Cp* ring protons clearly 249 
indicates the formation of the compounds. In the 
1
H NMR spectra of the complexes the N-H 250 
proton signals were observed as a singlet around 9.83-13.12 ppm. For complexes (5 and 6) the 251 
N-H proton resonance was observed at 8.93 and 8.87 ppm. The appearance of the N-H proton 252 
signals in the complexes indicates that the N-H group is not involved in bonding. The aromatic 253 
proton signals associated with the thiourea ligands were observed in the downfield region around 254 
7.00-9.14 ppm indicating the coordination of the thiourea ligand to the metal ion. Besides these 255 
resonance signals for the aromatic part of the ligand complexes (1, 4 and 7) displayed an unusual 256 
pattern of signal for the p-cymene moiety. The aromatic proton signal for the p-cymene ligand 257 
consisted of three doublets for complex (4) around 5.38-5.56 ppm whereas for complexes (1 and 258 
7) it showed two doublets and one triplet around 5.23-5.51 ppm instead of two doublets in the 259 
starting metal precursor. Also the methyl protons of isopropyl group displayed one doublet for 260 
complex (4) and two doublet of doublet for complexes (1 and 7) around 1.18-1.25 ppm as shown 261 
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in (Figure 1). This splitting of the aromatic and isopropyl protons of the p-cymene ligand is due 262 
to the desymmetrization of the p-cymene ligand upon coordination of the thiourea derived 263 
ligand. Complexes (1, 4 and 7) displayed septet around 2.74-2.81 ppm for the methine protons of 264 
the isopropyl group and singlet around 1.89-2.00 ppm for the methyl protons of the p-cymene 265 
ligand. In complexes (7-9) a singlet around 2.45-2.49 ppm was observed corresponding to the 266 
methyl protons of the pyridine ring of ligand L3. In rhodium and iridium complexes in addition, 267 
to the signals for the protons of the ligand a sharp singlet was observed around 1.52-1.66 ppm for 268 
the methyl protons of the pentamethylcyclopentadienyl ligand. Overall the 
1
H NMR spectra of 269 
the complexes exhibited the expected resonances and integration which is consistent with the 270 
formulation of the compounds. 271 
13
C {
1
H} NMR studies of metal complexes 272 
The 
13
C NMR spectra of the complexes further justify the coordination of the ligands and 273 
formation of complexes. The 
13
C NMR spectra of the complexes are provided in the 274 
supplementary information (Figures S10-S18). The 
13
C NMR spectra of the complexes displayed 275 
signals associated with the ligand carbons, p-cymene ligand carbons, methyl carbon of Cp* and 276 
ring carbon of Cp*. The carbon resonance of the thiocarbonyl (C=S) group appeared in the lower 277 
frequency region around 175.6-178.0 ppm. This shifting of carbon resonances of the thiourea 278 
derivatives clearly suggests its involvement in coordination to the metal ion. The aromatic 279 
carbons signals for the ligands were observed in the range of 116.2-163.3 ppm. In complexes (7-280 
9), the methyl carbon resonances of the pyridine ring were observed around 20.9-21.0 ppm. The 281 
ring carbon resonances of the p-cymene ligand were observed around 84.1-106.9 ppm. The 282 
methyl, methine and isopropyl carbon resonances of the p-cymene ligand were observed in the 283 
region around 17.1-30.7 ppm. The signals associated with the ring carbons of the Cp* ligand was 284 
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observed in the region around 89.3-97.4 ppm in contrast the methyl carbon resonances was 285 
observed as a sharp peak around 8.51-8.84 ppm. Overall results from the NMR spectral studies 286 
strongly support the formation of the metal complexes. 287 
Mass spectral studies of metal complexes 288 
The mass spectra of the thiourea complexes are presented in the supplementary 289 
information (Figures S19-S27) and the values are listed in the experimental section (2.4). The 290 
mass spectra of the complexes are consistent with the formulation and composition of the 291 
complexes. All these complexes displayed their molecular ion peaks at m/z: 464.0753, m/z: 292 
466.0820, m/z: 556.1381, m/z: 465.0685, m/z: 467.0784, m/z: 557.1355, m/z: 478.0902, m/z: 293 
480.0980 and m/z: 570.1572 which corresponds to [M-2H-2Cl+H]
+
 ion peak. The peak 294 
corresponding to the loss of the arene ring (arene = p-cymene/Cp*) was not observed in its mass 295 
spectrum which indicates the stronger metal to arene bond. 296 
Description of the crystal structures of complexes 297 
In addition to the spectroscopic analysis we were also able to confirm the coordination of 298 
the thiourea derivatives to the metal by carrying out the single crystal X-ray analysis. Our 299 
attempt to isolate the single crystal for all the complexes was unsuccessful; however we obtained 300 
single crystals for complexes (1, 5, 6, 7 and 8) respectively. Suitable single crystals were 301 
attached to a glass fiber and transferred into the Oxford Diffraction Xcalibur Eos Gemini 302 
diffractometer. The data and molecular structure of complex 1 presented here is to only confirm 303 
the structure and composition of the molecule. The ORTEP plot of complexes along with atom 304 
numbering scheme are shown in (Figures 2-4) respectively. The methyl groups of Cp* in 305 
complex (5) are disordered due to which the methyl groups in Cp* has large thermal ellipsoids 306 
The details regarding data collection and structure refinement parameters are summarized in 307 
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Table 1 and geometrical parameters including bond lengths, bond angles and metal atom 308 
involving ring centroid values are listed in Table 2. Complexes (1, 5 and 8) crystallized in 309 
monoclinic crystal system with space group P21/c whereas complex (6) crystallized with C2/c 310 
space group in monoclinic crystal system. Complex (7) crystallized in triclinic system with space 311 
group    . X-ray crystallographic studies showed that these complexes contained the cationic 312 
species of general formula [(arene)M(L)Cl] [(arene) = p-cymene, Cp*; M = Ru, Rh and Ir; (L) = 313 
(L1-L3) ] and counter anion chloride. These complexes featured a regular three legged “piano-314 
stool” geometry in which the coordination sites around the metal is occupied by the arene ligand 315 
(arene = p-cymene/Cp*) in a η6/η5 manner, terminal chloride and a chelating N,S- ligand. The 316 
metal atom shows pseudo-octahedral coordination geometry wherein the arene ligand occupies 317 
the three facial coordination sites acting as seat of “piano-stool” and nitrogen and sulfur donor 318 
atoms from thiourea derivatives (L1-L3) and terminal chloride acting as legs. The molecular 319 
structures of these complexes revealed that the ligands (L1-L3) coordinated metal in a neutral 320 
bidentate chelating N,S- manner through pyridyl nitrogen N(1) in complexes (1, 7 and 8), 321 
pyrimidyl nitrogen N(1) in complexes (5 and 6) and thione sulfur S(1). This coordination of the 322 
ligands in a bidentate manner led to the formation of a six-membered chelated ring with the 323 
metal center. The arene ring is essentially planar and the metal to centroid of the arene ring 324 
distances are {1.696 (1), 1.789 (5), 1.794 (6), 1.689 (7) and 1.789 (8) Å}. The iridium to centroid 325 
distance is slightly larger than the ruthenium/rhodium centroid distances (Table 2). Further as per 326 
the literature survey of these ligands these are known to exhibit several coordination modes but 327 
in these half-sandwich d
6
 metal complexes reported here the preferable mode of coordination of 328 
these ligands is only in a bidentate к2(N,S) fashion. The deprotonation of the amido hydrogen 329 
which was expected to alter the coordination behavior of these ligands was also not observed as 330 
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evidenced by 
1
H NMR and molecular structures. There is significant delocalization of π-electron 331 
density in the six-membered chelate ring as evidenced from the bond distances of the complexes 332 
which was found to be in the range of 1.33-1.69 Å.
[31]
 The phenyl ring is effectively planar to 333 
that of the chelate ring. Further the C-S bond distances in these complexes was found to be in the 334 
range of 1.686-1.700 Å suggesting that it is intermediate between single C-S (1.82 Å) and double 335 
C=S (1.56 Å) bond distances.
[32]
 The bond lengths in these complexes are normal and consistent 336 
with the к2-N,S- coordination of the thiourea derivatives which correlates well with reported 337 
values for similar complexes.
[19,33-35]
 The metal to nitrogen bond distances is comparatively 338 
shorter than the metal to sulfur bond distances (Table 2). The M-Cl bond lengths in these 339 
complexes shows no significant differences and was found to be in the range of 2.39-2.40 Å 340 
which is comparable to reported literature values.
[33,34]
 With respect to the bond angle values 341 
N(1)-M(1)-S(1), N(1)-M(1)-Cl(1), S(1)-M(1)-Cl(1) these are close to 90° suggesting pseudo-342 
octahedral geometry around the metal center (Table 2). Overall all the geometrical parameters 343 
are as anticipated. 344 
Non-covalent interactions 345 
Further the crystal packing diagrams of these complexes revealed several weak 346 
intermolecular interactions. For instance the crystal structure of complex (5) crystallized with 347 
solvent molecule (CHCl3) which showed intermolecular hydrogen bonding. The chloride 348 
counterion in complex (5) displayed three different types of intermolecular hydrogen bonding, 349 
C-H∙∙∙Cl (2.510 Å), N-H(4)∙∙∙Cl (2.246 Å), N-H(3)∙∙∙Cl (2.420 Å) and C-H∙∙∙Cl (2.909 Å) as 350 
shown in (Figure 5). Also it possessed C-H∙∙∙Cl (2.921 Å) interaction between the chloride 351 
attached to rhodium and hydrogen atom of phenyl ring and C-H∙∙∙S (2.788 Å) interaction 352 
between thione sulfur and hydrogen atom of phenyl ring (Figure 5). The crystal structure of 353 
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complex (7) exhibits two different types of C-H∙∙∙Cl (2.848 and 2.869 Å) interactions between 354 
the chloride counterion and H-atom of phenyl ring and methyl hydrogen of p-cymene ring. It 355 
also showed N-H(2)∙∙∙Cl (2.291 Å), N-H(3)∙∙∙Cl (2.425 Å) interactions between the amide 356 
hydrogen and chloride counter ion [Figure 6 (a]. Further the crystal structure of complex (8) is 357 
stabilized by C-H∙∙∙Cl (2.704 and 2.863 Å) interaction between the methyl-H atom of Cp*, and 358 
N-H(3)∙∙∙Cl (2.320 Å), N-H(4)∙∙∙Cl (2.277 Å) interaction between chloride counter ion and amide 359 
hydrogen [Figure 6 (b)]. These weak intermolecular interactions play a crucial role in the 360 
formation of supramolecular architectures. 361 
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Table 1 Crystal data and structure refinement parameters of complexes. 362 
Structures were refined on F0
2
: wR2 = [Σ[w(F0
2
 - Fc
2
)
2] / Σw(F0
2
)
2
]
1/2
, where w
-1
 = [Σ(F0
2
)+(aP)
2
+bP] and P = [max(F0
2
, 0)+2Fc
2
]/3 363 
Compounds [1]Cl [5]Cl CHCl3 [6]Cl [7]Cl [8]Cl 
Empirical formula C22H25N3Cl3SRu C22H26Cl5N4SRh C21H25N4Cl2SIr C23H27Cl2N3SRu C23H28Cl2N3SRh 
Formula weight 570.93 658.69 628.61 549.03 552.35 
Temperature (K) 293(2) 295(2) 295(2) 296.5(4) 295.88(18) 
Wavelength (Å) 0.71073 0.71073 0.71073 0.71073 0.71073 
Crystal system monoclinic monoclinic monoclinic triclinic monoclinic 
Space group P21/c P21/c C2/c     P21/c 
a (Å)/α (°) 13.3257(10)/90 8.0190(7)/90  18.3824(11)/90 10.2397(8)/91.759(5)  13.8075(8)/90 
b (Å)/β (°) 13.8131(10)/90.279(8) 13.1219(8)/96.088(7) 16.4907(8)/116.016(8) 10.2855(6)/104.690(6) 7.8091(4)/105.402(6) 
c (Å)/γ (°) 13.0173(12)/90 26.9485(16)/90 18.7528(12)/90 11.9684(7)/102.167(6) 23.1017(12)/90 
Volume (Å3) 2396.1(3) 2819.7(3) 5108.7(6) 1187.20(14) 2401.5(2) 
Z 4 4 8 2 4 
Density (calc) (Mg/m-3) 1.583 1.552 1.635 1.534 1.528 
Absorption coefficient 
 (µ) (mm-1) 
1.091 1.172 5.532 0.988 1.036 
F(000) 1156 1328 2448 558 1128 
Crystal size (mm3) 0.29 x 0.21 x 0.15 0.25 x 0.23 x 0.21 0.49 x 0.36 x 0.25 0.25 x 0.23 x 0.21 0.25 x 0.23 x 0.21 
Theta range for data 
collection 
3.130 to 29.069° 3.197 to 28.974° 3.491 to 28.858° 3.246 to 29.110° 3.318 to 29.044° 
Index ranges -14<=h<=18, -12<=k<=18, -
17<=l<=9 
-10<=h<9, -10<=k<=17, -
27<=l<=36 
-24<=h<=23, -21<=k<=18, -
13<=l<=25 
-13<=h<10, -13<=k<=14, -
15<=l<=16 
-18<=h<=9, -10<=k<=5, -
31<=l<27 
Reflections collected 7081 10440 10138 8283 9741 
Independent reflections 4978 [R(int) = 0.0353] 6211 [R(int) = 0.0257] 5726 [R(int) = 0.0556] 5355 [R(int) = 0.0559] 5504 [R(int) = 0.0276] 
Completeness to theta = 
25.00° 
99.9 % 97.6 % 99.2 % 99.4 % 99.6 % 
Absorption correction Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Semi-empirical from 
equivalents 
Refinement method Full-matrix least-squares on F2 Full-matrix least-squares on 
F2 
Full-matrix least-squares on F2 Full-matrix least-squares on F2 Full-matrix least-squares on 
F2 
Data/restraints/parameters 4978/0/271 6211/157/405 5726/0/267 5355/0/271 5504/0/271 
Goodness-of-fit on F2 1.063 1.086 1.063 1.059 1.060 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0721, wR2 = 0.1868 R1 = 0.0600, wR2 = 0.1419 R1 = 0.0562, wR2 = 0.1121 R1 = 0.0553, wR2 = 0.1298 R1 = 0.0427, wR2 = 0.0913 
R indices (all data) R1 = 0.0985, wR2 = 0.2130 R1 = 0.0791, wR2 = 0.1551 R1 = 0.0723, wR2 = 0.1195 R1 = 0.0699, wR2 = 0.1430 R1 = 0.0567, wR2 = 0.0974 
Largest diff. peak and hole  
( e.Å-3) 
2.529 and -0.955 0.932 and -0.625 3.511 and -3.039 0.949 and -0.802 0.434 and -0.452 
CCDC No.  1581360 1581361 1581362 1581363 
19 
 
 Table 2 Selected bond lengths (Å) and bond angles (°) of complexes. 364 
Complex 1 5 6 7 8 
M(1)-CNT 1.696 1.789 1.794 1.689 1.789 
M(1)-N(1) 2.122(6) 2.101(3) 2.110(5) 2.109(4) 2.101(3) 
M(1)-S(1) 2.3740(18) 2.3411(9) 2.3616(16) 2.3768(12) 2.3411(9) 
M(1)-Cl(1) 2.4097(18) 2.3992(10) 2.3962(16) 2.4009(12) 2.3992(10) 
C=S(1) 1.699(7) 1.694(3) 1.700(6) 1.686(4) 1.694(3) 
N(1)-M(1)-S(1) 85.99(15) 85.08(8) 86.15(13) 84.18(10) 85.08(8) 
N(1)-M(1)-Cl(1) 86.14(16) 88.56(8) 88.14(13) 86.88(9) 88.56(8) 
S(1)-M(1)-Cl(1) 85.74(7) 90.11(44) 87.34(6) 86.16(4) 90.11(4) 
CNT represents the centroid of the arene ring and (M = Ru, Rh and Ir) 365 
Chemosensitivity studies 366 
The response of HCT-116, MIA PaCa-2 and ARPE-19 cells to the thiourea ligands (L1-367 
L3) and its metal complexes (1-9) are provided in Table 3. The thiourea ligands (L1-L3) were 368 
found to be inactive against both the cell line with IC50 value > 100. Upon complexation of 369 
thiourea ligands all the complexes displayed cytotoxicity against both cancer cell lines. 370 
Complexes (4-6) with ligand L2 were found to exhibit moderate activity against both the cell 371 
lines with IC50 value in the range of 33.1 ± 0.39 to 77.4 ± 2.71 M. Complexes (1-3) with ligand 372 
L1 and (7-9) with ligand L3 possessed similar cytotoxicity against both HCT-116 and Mia-PaCa-373 
2 cell line with IC50 value in the range of 9.10 ± 0.09 to 18.2 ± 3.25 M. These complexes were 374 
found to be more active as compared to complexes (4-6). However, all these thiourea compounds 375 
were found to be less cytotoxic as compared to cisplatin whose IC50 value is 2.78 M against 376 
HCT-116 and 3.15 M against MIA-PaCa2 cell lines. Complex (8) was found to possess the 377 
highest cytotoxicity among all other complexes against HCT-116 cell line with IC50 value of 378 
9.16 ± 0.84 M whereas complex (9) was the most potent against Mia-PaCa-2 cell line with IC50 379 
value of 9.10 ± 0.09 M. The response of ARPE-19 non-cancer cell lines is presented in Table 3 380 
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and corresponding selectivity indices are presented in Figure 7. With regards to potency, 381 
statistically significant differences between the response of cancer cells lines and ARPE-19 cells 382 
were observed for all complexes with the exception of complex (4). In the case of complexes (1, 383 
3, 7 and 9) statistically significant differences between the response of MIA-PaCa-2 (but not 384 
HCT-116) and ARPE-19 cells was observed suggesting that some selectivity for MIA-PaCa-2 385 
cells exists in vitro (Table 3). The selectivity index (SI) is shown in Table 4 which is defined as 386 
the ratio of IC50 values in ARPE19 cells divided by the IC50 for either HCT-116 or MIA-PaCa-2 387 
cells. With regards to selectivity, Figure 7 demonstrates that complexes (5, 6 and 8) have greater 388 
selectivity for HCT-116 cells than cisplatin under identical experimental conditions. In some 389 
cases (complexes 1, 3 and 9) enhanced selectivity towards the MIA-PaCa-2 as opposed to the 390 
HCT-116 cell line is obtained. The IC50 and selectivity index values of these compounds provide 391 
an ideal platform for the design of thiourea complexes possessing high cytotoxicity. 392 
  393 
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Table 3 IC50 values of thiourea ligands (L1-L3) and complexes (1-9) along with cisplatin against 394 
HCT-116 and MIA-PaCa-2 cancer cell line. Each value represents the mean ± standard deviation 395 
from three independent experiments. Statistical analysis comparing the response of cancer cell 396 
lines (HCT-116 or MIA-PaCa-2) to non-cancer ARPE-19 cells was performed by a two tailed 397 
students t-test with * and ** representing P values of < 0.05 and < 0.01 respectively. 398 
Compounds IC50 (µM) 
 HCT-116 MIA-PaCa-2 ARPE-19 
L1 IC50>100 IC50>100 IC50>100 
L2 IC50>100 IC50>100 IC50>100 
L3 IC50>100 IC50>100 IC50>100 
Complex 1 17.52 ± 2.95 10.05 ± 0.17** 21.31 ± 3.53 
Complex 2 9.69 ± 0.97** 10.17 ± 0.37** 19.46 ± 2.57 
Complex 3 15.38 ± 3.21 9.96 ± 0.11* 24.14 ± 8.33 
Complex 4 68.44 ± 5.82 77.44 ± 2.71 67.52 ± 16.98 
Complex 5 44.82 ± 11.70* 33.66 ± 3.96** 84.41 ± 16.51 
Complex 6 35.59 ± 7.35** 33.17 ± 0.39** 66.28 ± 3.97 
Complex 7 18.23 ± 3.25 16.75 ± 0.42** 20.82 ± 0.57 
Complex 8 9.16 ± 0.84* 9.48 ± 0.32* 15.75 ± 2.87 
Complex 9 16.02 ± 2.13 9.10 ± 0.09** 19.78 ± 1.80 
Cisplatin 2.78 ± 1.40 3.15 ± 0.10 3.43±0.48 
IC50 = concentration of the drug required to inhibit the growth of 50% of the cancer cells (µM). 399 
Table 4 Selectivity index of complexes (1-9) and cisplatin in HCT-116 and MIA-PaCa-2 cancer 400 
cell lines. The selectivity index (SI) was calculated as the IC50 for ARPE-19 cells divided by the 401 
IC50 for either HCT-116 or MIA-PaCa-2 cells. 402 
Compounds HCT-116 MIA-PaCa-2 
Complex 1 1.21 2.12 
Complex 2 2 1.91 
Complex 3 1.56 2.42 
Complex 4 0.98 0.87 
Complex 5 1.88 2.5 
Complex 6 1.86 1.99 
Complex 7 1.14 1.242 
Complex 8 1.71 1.66 
Complex 9 1.234 2.173 
Cisplatin 1.23 1.08 
 403 
 404 
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Conclusion 405 
In summary, we have successfully synthesized ruthenium, rhodium and iridium half-406 
sandwich complexes containing thiourea derivatives. These complexes were fully characterized 407 
by various spectroscopic studies and molecular structures were established by single crystal X-408 
ray analysis. X-ray crystallographic studies of the complexes revealed that the thiourea 409 
derivatives coordinated metal in a neutral bidentate chelating manner coordinating metal through 410 
nitrogen atom from pyridine or pyrimidine and thione sulfur. The chemosensitivity studies of the 411 
thiourea derivatives and complexes carried out against HCT-116, MIA-PaCa-2 and ARPE-19 412 
cell lines showed that the thiourea ligands are not cytotoxic but after complexation however, the 413 
complexes possessed cytotoxicity. Whilst the potency of these complexes is generally less than 414 
cisplatin, this study demonstrates that several complexes have greater selectivity for cancer cell 415 
lines (with some showing specific selectivity for MIA-PaCa-2 pancreatic cancer cells) than 416 
cisplatin under identical experimental conditions in vitro. Further development of these 417 
complexes is required to enhance selectivity further and explore mechanism of action responsible 418 
for the differential cytotoxic effects observed. 419 
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